In contrast to the NCCN recommendations, ELN 2017 classification stratifies AML patients with NPM1mut/FLT3-ITDlow as favorable while only those patients with NPM1wt/FLT3-ITDhigh are attributed to the adverse prognostic subgroup [3]. Here, FLT3 is linked to acute myeloid leukemia.